作者
Meletios A Dimopoulos, Philippe Moreau, Antonio Palumbo, Douglas Joshua, Ludek Pour, Roman Hájek, Thierry Facon, Heinz Ludwig, Albert Oriol, Hartmut Goldschmidt, Laura Rosiñol, Jan Straub, Aleksandr Suvorov, Carla Araujo, Elena Rimashevskaya, Tomas Pika, Gianluca Gaidano, Katja Weisel, Vesselina Goranova-Marinova, Anthony Schwarer, Leonard Minuk, Tamás Masszi, Ievgenii Karamanesht, Massimo Offidani, Vania Hungria, Andrew Spencer, Robert Z Orlowski, Heidi H Gillenwater, Nehal Mohamed, Shibao Feng, Wee-Joo Chng
发表日期
2016/1/1
期刊
The Lancet Oncology
卷号
17
期号
1
页码范围
27-38
出版商
Elsevier
简介
Background
Bortezomib with dexamethasone is a standard treatment option for relapsed or refractory multiple myeloma. Carfilzomib with dexamethasone has shown promising activity in patients in this disease setting. The aim of this study was to compare the combination of carfilzomib and dexamethasone with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Methods
In this randomised, phase 3, open-label, multicentre study, patients with relapsed or refractory multiple myeloma who had one to three previous treatments were randomly assigned (1:1) using a blocked randomisation scheme (block size of four) to receive carfilzomib with dexamethasone (carfilzomib group) or bortezomib with dexamethasone (bortezomib group). Randomisation was stratified by previous proteasome inhibitor therapy, previous lines of treatment, International Staging System stage, and planned …
学术搜索中的文章
MA Dimopoulos, P Moreau, A Palumbo, D Joshua… - The Lancet Oncology, 2016